Access our 2024 TIDES Europe Investor Recap Call
TIDES US 2024 Presentation
Starting from an enzyme with trace activity and preference for the undesired diastereoisomer, 11 rounds of enzyme evolution were performed.
Enzymatic RNA Manufacturing
Codexis provides a range of RNA manufacturing services using proprietary enzymatic technologies to enable nucleic acid therapeutics development. Leveraging the Enzyme-Catalyzed Oligonucleotide (ECO) SynthesisTM manufacturing platform, sequences with modified RNA bases and tissue-targeting moieties can be synthesized to maximize yield and purity, while adopting economically sound, scalable pathways. Our technology operates under aqueous conditions that are milder than the current solid phase oligonucleotide synthesis (SPOS) processes, thereby significantly reducing the complexity of impurities and the use of organic solvents during synthesis.
Coming soon, Codexis’ ECO Synthesis Innovation Lab will take a collaborative approach to design a project development plan that works for you. We can customize analytical methods, tailor final deliverable scales, and provide additional custom services to meet your needs. Additionally, Codexis enables technology transfer of our process to your chosen manufacturing site for scaling up and production under GMP.
Why partner with Codexis?
- Improved quality
- Higher scalability
- Higher yield
- Custom pharma manufacturing expertise
- Path to GMP production
- Derisked process development
- Dedicated service team
Scalability
The ECO Synthesis technology streamlines siRNA manufacturing at large scales, enabling an increase in volumetric productivity, thus lowering lead times and costs. While doing so, it maintains higher purity of the final drug substance by reducing Class IV impurities associated with traditional phosphoaramidite chemistry-based methods.
Process Development
Codexis’ simple, two-step ECO Synthesis process enables faster process development. Our alliance management team partners with you to customize analytical services, manufacturing scale, and develop a timeline that minimizes project delays and maximizes risk mitigation for your asset. Additionally, we leverage proprietary AI/ML powered computational tools to further de-risk development of your unique siRNA sequence.
